The Markets Are Open

JPMorgan Chase Falls Another 2% (JPM, ISRG, GRPN, BIDU, VTUS)
JPMorgan Chase & Co. (NYSE:JPM) stock fell 1.95% to $36.23 in the early hour after the company announced today that Ina Drew, Chief Investment Officer, has made the decision to retire from the firm. Ina has served the firm for more than 30 years, most recently as head of our Chief Investment Office.  Earlier last week, the company also announced that since March 31, 2012, its Chief Investment Office has had hefty mark-to-market losses in its synthetic credit portfolio that has proved to be more risky than expected. JPMorgan said it now estimates its Corporate business, within the Corporate/Private Equity segment, to incur a net loss of about $800 million, which excludes Private Equity results and litigation expense.

Intuitive Surgical, Inc. (NASDAQ:ISRG) stock decreased 1.05% to $553.06 in the morning hour. The company today reported that equity awards approved by the Compensation Committee of the Board of Directors, which consists entirely of Independent Directors, were made to 51 new employees. 51 employees were granted options to purchase an aggregate of 32,785 shares of the Company's common stock.

Baidu.com, Inc. (ADR) (NASDAQ:BIDU) shares climbed 0.94% to $123.38 in the early hour. However, the company has declined 18% in the last one month. The latest earnings didn’t impress investors much and hence the stock went into correction mode. Nevertheless, the company has strong potential in terms of business growth considering its entry in the mobile platform.
The company posted net profit of $299.0 million, up 75.90% year-over-year. On per share basis, the company earned $0.87 a share, ahead of analysts’ estimates of $0.84 a share. Revenue during the quarter jumped 75% year-over-year to $677.1 million, in-line with analysts’ estimates of $677.51 million. Operating profit during the quarter surged 75.10% to $332.1 million.

Ventrus Biosciences Inc (NASDAQ:VTUS) stock soared 19.43% to $13.09 on an above average volume after the company today reported positive results from its Phase 3, randomized, double-blind, placebo-controlled clinical trial of diltiazem hydrochloride cream (VEN 307) in patients with anal fissures. Ventrus' development partner, S.L.A. Pharma, has completed most of the outputs for the statistical analysis plan of the Phase 3 trial, and Ventrus is pleased to communicate the data that they have generated.